APCCC 2024: How to Select ADT and an ARPI Based on Cardiovascular Risk Profile
APCCC 2024, prostate cancer, cardiovascular risks from prostate cvancer treatment, androgen deprivation therapy (ADT), androgen deprivation receptor inhibitor (ARPI), ADT and an ARPI based on cardiovascular risk profile, GnRH agonists, leuprolide, relugolix, HERO trial, Enzalutamide, follicle stimulating hormone (FSH), darolutamide.